CINXE.COM
Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments
<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles."> <meta property="og:title" content="Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments"> <meta name="twitter:description" content="Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles."> <meta name="twitter:title" content="Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css"> <!-- Editor Styles --> <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style> <!-- Added by GoogleAnalytics4 integration --> <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script> <!-- /Added by GoogleAnalytics4 integration --> <link rel="canonical" href="https://oxfordglobal.com/discovery-development/resources/beyond-traditional-therapeutics-how-digital-therapeutics-reshape-neurological-and-neuropsychiatric-treatments"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Copy%20of%20Featured%20Image%20(6).png"> <meta property="og:image:width" content="1200"> <meta property="og:image:height" content="800"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Copy%20of%20Featured%20Image%20(6).png"> <meta property="og:url" content="https://oxfordglobal.com/discovery-development/resources/beyond-traditional-therapeutics-how-digital-therapeutics-reshape-neurological-and-neuropsychiatric-treatments"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="discovery-development"> <div class="body-wrapper hs-content-id-177028096592 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/discovery-development" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/discovery-development/events/discovery-development-europe-2025" class="pill center"> <div class="b">Discovery & Development Europe 2025</div> <div class="heading-smallcaps"> 01 - 02 Jul 2025 | Basel, Switzerland </div> </a> <a href="/discovery-development/events/discovery-development-us-2025" class="pill center"> <div class="b">Discovery & Development US 2025</div> <div class="heading-smallcaps"> 02 - 03 Oct 2025 | San Diego, CA </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10"> <!-- Individual Online Activity --> <div class="online-activity"> <a href="/discovery-development/online#Controlled%20Release%20Formulations" class="cta" target="_blank"> <h3 class="other-resources">26/06/24 - Controlled Release Formulations</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>We empower scientific decision-makers from the world’s most innovative biopharma organisations to make informed pipeline decisions in early R&D, accelerating their route from target ID to novel clinical candidate.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>Our community extends across the entire early R&D ecosystem, including biopharma, solution providers, start-ups, academics, and investors.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>Scientific & technical insights on the latest targets, platforms and processes impacting drug discovery & development.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Discovery & Development Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/discovery-development/resources/biomedgpt-adopting-a-generalist-approach-to-biomedical-ai" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery%20and%20Development/BiomedGPT%20Adopting%20a%20Generalist%20Approach%20to%20Biomedical%20AI%20.png" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/discovery-development/resources/biomedgpt-adopting-a-generalist-approach-to-biomedical-ai">BiomedGPT: Adopting a Generalist Approach to Biomedical AI </a> </h3> <div class="resource-abstract"> <span class="resource-date">11/11/24 - </span> BiomedGPT, a versatile AI tool used for biomedical research demonstrated impressive results across a wide range of healthcare tasks. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/discovery-development/resources/the-application-of-rnai-therapeutics-for-cardiovascular-disease-treatment">07/11/24 - The Application of RNAi Therapeutics for Cardiovascular Disease Treatment</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/discovery-development/resources/ai-ml-advancements-in-drug-formulation-the-potential-of-self-driving-labs">16/10/24 - AI/ML Advancements in Drug Formulation – The Potential of Self-Driving Labs </a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/discovery-development/resources/sponsored/case-studies/ardigen/advancing-drug-discovery-through-innovative-technologies-strategic-collaboration"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/Advancing%20Drug%20Discovery%20Mock%20Up.png" class="sponsor-resource-bubble-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Advancing Drug Discovery Through Innovative Technologies & Strategic Collaboration </h3> <div class="resource-abstract"> A Concise Report Featuring Insights From The Prominent Thought Leaders Of Discovery & Automate 2024 </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Industry Spotlights & Insight Articles </div> <h1 class="heading"> Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments </h1> <div class="byline"> Edited by Lucia Simmen | 09 April 2024 </div> <div class="abstract"> Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Copy%20of%20Featured%20Image%20(6).png" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap"> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"><strong>Introduction to the Digital Therapeutics Landscape</strong></p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">Digital Therapeutics (DTx) is a subcategory of digital health which represents s group of technologies, products and services across healthcare and wellness industries. The global digital health in neuroscience market size was valued at USD 32.3 billion in 2023. The market is <a href="https://www.grandviewresearch.com/industry-analysis/digital-health-neurology-market-report#:~:text=Market%20Size%20%26%20Trends,22.5%25%20from%202024%20to%202030" rel="noopener" target="_blank"><span style="color: #4a6ee0;">expected to grow at a compound annual growth rate (CAGR) OF 22.5% from 2024 to 2030</span></a>. Ongoing digitization efforts and transformation of the healthcare sector are driving this growth.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">As a result, digital therapeutics (DTx) have received significant attention from industry stakeholders, regulatory bodies, and investors. For instance, the USFDA sanctioned the <a href="https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program" rel="noopener" target="_blank"><span style="color: #4a6ee0;">Breakthrough Device Designation Program </span></a>for granting approvals to digital therapeutics. As of 2022, <a href="https://www.fiercepharma.com/sponsored/advancing-access-digital-therapeutics#:~:text=Over%20the%20last%20five%20years,a%20number%20of%20therapeutic%20categories" rel="noopener" target="_blank"><span style="color: #4a6ee0;">the FDA has approved over 35 digital therapeutics </span></a>and this number is expected to grow.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">Prescription digital therapeutics must go through regulatory approval and have sufficient clinical data to back claims that they are suitable options for treating neurological disorders. Whereas non-prescription therapeutics don't need clinical data to enter the market.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">The application of DTx in the neuroscience field deserves further exploration. Due to the complexity of the brain, traditional therapeutics are not always sufficient in treating neurological and neuropsychiatric conditions. </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">DTx could have a major impact on neurology and offer potential treatments for neurological diseases. Therefore, commercialisation and clinical application of digital therapeutics are growing and there is a demand for expansion to new clinical areas.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"><strong>Related: </strong></p> <ul> <li style="text-align: justify;"><a href="https://oxfordglobal.com/biomarkers/resources/enhancing-patient-care-exploring-the-role-of-digital-biomarkers-in-patient-centric-healthcare">Enhancing Patient Care: Exploring the Role of Digital Biomarkers in Patient-Centric Healthcare</a></li> <li style="text-align: justify;"><a href="https://oxfordglobal.com/biomarkers/resources/real-world-data-analytics-in-biomarkers">The Power of Real-World Data Analytics in Biomarker Discovery: A Game-Changer in Medical Research</a></li> </ul> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">The main advantage of digital therapeutics is that <a href="https://www.nature.com/articles/s41746-023-00777-z#:~:text=DTx%20have%20advantages%20in%20terms,within%20the%20conventional%20medical%20system" rel="noopener" target="_blank"><span style="color: #4a6ee0;">they require minimal development costs compared with pharmaceuticals (1%) and the development period is approximately half</span></a>, making them an attractive option for stakeholders. Furthermore, digital therapeutics can be used at multiple points of intervention along the patient journey, such as monitoring, medication adherence, and behavioural engagement. </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"><strong>Case Studies</strong></p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p><strong>1. Treating Major Depressive Disorder with Digital Therapeutics</strong></p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">According to a recent <a href="https://otsuka-us.com/news/rejoyn-fda-authorized#:~:text=Rejoyn%20is%20a%20prescription%20digital,intended%20to%20reduce%20MDD%20symptoms" rel="noopener" target="_blank"><span style="color: #4a6ee0;">press release</span></a>, the FDA has cleared Otsuka Pharmaceutical's digital treatment for major depressive disorder (MDD) offering a new option for millions of people who struggle with this complex mental health condition. This is a landmark study as it’s the first prescription digital therapeutic authorized for the treatment of depression symptoms.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">The treatment, Rejoyn, is a smartphone-based treatment for major depressive disorder symptoms and was jointly developed with Click Therapeutics, a digital therapeutics company. Rejoyn is intended for use alongside antidepressants. </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">Rejoyn is a six-week treatment program to enhance cognitive control of emotion through a combination of clinically validated cognitive emotional training exercises for the brain and short therapeutic lessons. Rejoyn is designed to target neural networks affected by depression and is hypothesized to leverage the brain's inherent neuroplasticity to alter those connections leading to symptom reduction over time.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">The clearance of Rejoyn is based on data from a 3-month, multicentre, randomized, and controlled trial of 386 participants, aged 22 to 64 and diagnosed with MDD. Participants in this sample were also on antidepressant medication. In the trial, patients were randomly assigned to receive either Rejoyn or a sham control app.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">Participants treated with Rejoyn showed a significant improvement in depression symptom severity. Furthermore, patients in the Rejoyn sample showed continued improvement one month after completing the treatment program.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">Only 1 in 3 patients diagnosed with depression who receive antidepressants as their first-line treatment are successful. To address this, patients need access to new options like Rejoyn that capitalize on effective treatment strategies. John Kraus, Executive Vice President and Chief Medical Officer at Otsuka, emphasised this point: "While traditional approaches are often effective, many are left with only a partial response to treatment."</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p><strong>2. Using Digital Biomarkers to Predict Disease Progression in Parkinson's Disease</strong></p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">MSD has joined forces with Koneksa, a healthcare technology company developing evidence-based digital biomarkers. LEARNS is an observational study that explores the <a href="https://koneksahealth.com/about/news/koneksa-announces-merck-joins-data-syndication-partnership-program-around-parkinsons-digital-biomarkers-observational-study/" rel="noopener" target="_blank"><span style="color: #4a6ee0;">potential of digital biomarkers in evaluating and predicting disease progression in Parkinson's disease patients</span></a>.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">Digital biomarkers that can be assessed remotely using smartphones and wearable devices could potentially help diagnose Parkinson's and allow patients to begin treatment while still in the early stages.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">Related:</p> <ul> <li style="text-align: justify; margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm;"><a href="https://oxfordglobal.com/biomarkers/resources/speech-analysis-tool-for-the-early-detection-of-alzheimers-handed-to-linus-health-in-acquisition" rel="noopener" target="_blank">Speech-Analysis Tool for the Early Detection of Alzheimer's Handed to Linus Health in Acquisition</a></li> </ul> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">Well-validated measures of Parkinson's disease progression are essential to informing drug development. The LEARNS study aims to evaluate the reliability and responsiveness of biomarkers across time using mobile electroencephalogram (EEG), wearables, and smartphone-based assessments in neurological and sleep disorders. This technology allows researchers to measure the brain's electrical activity and identify evidence of neurological conditions such as Parkinson's disease.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">The LEARNS study seeks to <a href="https://parkinsonsnewstoday.com/news/merck-joins-study-digital-biomarkers-parkinsons-disease/" rel="noopener" target="_blank"><span style="color: #4a6ee0;">examine disease progression for 12 months in up to 70 people with Parkinson's disease</span></a>. The clinical data collected from the LEARNS study will shape the future development of digital biomarkers of disease progression in Parkinson's disease. </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"><strong>Conclusion </strong></p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">There is an element of ambiguity and scepticism towards DTx because these devices are still in their preliminary stages, and there are still gaps in the research. For example, <a href="https://www.nature.com/articles/s41746-020-00370-8" rel="noopener" target="_blank"><span style="color: #4a6ee0;">how and whether DTx will be evaluated against conventional therapeutics </span></a>through comparative studies is yet to be explored. </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; text-align: justify; padding-left: 0cm;">Successfully applied use of DTx is dependent on strengthening real-world evidence-based validation which is what these two case studies offer. These research projects illustrate how digital therapeutics can help monitor and treat neurological and neuropsychiatric conditions. Overall, DTx have targeted neurological and psychiatric conditions with significant unmet needs that are difficult to manage with existing traditional therapeutics.</p> <div class="content-body-footer"> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/discovery-development/resources/cobenfy-a-critical-breakthrough-in-schizophrenia-treatment-in-over-30-years"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/FDA%20approves%20Bristol%20Myer%20Squibb%E2%80%99s%20first%20novel%20schizophrenia%20drug%20in%2035%20years.png" class="cover-graphic-image"> </div> </a><div class="content"><a href="/discovery-development/resources/cobenfy-a-critical-breakthrough-in-schizophrenia-treatment-in-over-30-years"> <h4> Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years </h4> <div class="abstract"> According to a recent press release, the US FDA has approved Cobenfy, a first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults. </div> <div class="read-more"> <a href="/discovery-development/resources/cobenfy-a-critical-breakthrough-in-schizophrenia-treatment-in-over-30-years" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/discovery-development/resources/university-of-pennsylvania-and-fast-to-develop-aav-gene-therapy-for-angelman-syndrome"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/University%20of%20Pennsylvania%20and%20FAST%20to%20Develop%20AAV%20Gene%20Therapy%20for%20Angelman%20Syndrome.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/discovery-development/resources/university-of-pennsylvania-and-fast-to-develop-aav-gene-therapy-for-angelman-syndrome"> <h4> University of Pennsylvania and FAST to Develop AAV Gene Therapy for Angelman Syndrome </h4> <div class="abstract"> The collaboration hopes to develop a AAV gene therapy for rare genetic disease Angelman syndrome. </div> <div class="read-more"> <a href="/discovery-development/resources/university-of-pennsylvania-and-fast-to-develop-aav-gene-therapy-for-angelman-syndrome" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things Discovery & Development </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177049184347">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script> <!-- HubSpot performance collection script --> <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script> <!-- Start of HubSpot Analytics Code --> <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/discovery-development\/resources\/beyond-traditional-therapeutics-how-digital-therapeutics-reshape-neurological-and-neuropsychiatric-treatments"]); _hsq.push(["setPageId", "hubdb-177028096592-7642658-170712574368"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177028096592-7642658-170712574368", "legacyPageId": "hubdb-177028096592-7642658-170712574368", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177028096592, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script> <!-- End of HubSpot Analytics Code --> <script type="text/javascript"> var hsVars = { render_id: "9b756b89-2d4d-4404-b053-ddb557fe8405", ticks: 1732336885244, page_id: 177028096592, dynamic_page_id: "hubdb-177028096592-7642658-170712574368", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177028096592-7642658-170712574368", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>